← All trials
NCT06614387
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2024
- Primary completion
- Apr 30, 2028
- Completion date
- Nov 30, 2028
- First posted
- Sep 26, 2024
- Last posted
- Sep 26, 2024
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Children's Memorial Health Institute, PolandLead sponsor
- Children's Memorial Health Institute, PolandSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.